Novo Nordisk to present 63 abstracts at 74th Annual American Diabetes Association Scientific Sessions in San Francisco, CA

Novo Nordisk, the world’s leading diabetes care company, will unveil 63 abstracts containing safety and efficacy data from our class-leading portfolio of diabetes products at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA on 13–17 June. Following is a selection of abstracts that will be presented:

• Liraglutide 3.0 mg for Weight Management in Obese/Overweight Adults with Type 2 Diabetes: Results from the SCALE™ Diabetes 56-Week Randomized, Double-blind, Placebo-controlled Trial (Abstract #97-OR)
• One-year Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes (Abstract #65-OR)
• Impact of BMI on HbA1c Reduction, Hypoglycaemia Rates and Insulin Requirements in Response to IDegLira in Patients with Type 2 Diabetes (Abstract #66-OR)
• IDegLira Efficacy Across the Range of Disease Progression in Type 2 Diabetes (Abstract #0067-OR)
• Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes (T2DM) and Moderate Renal Impairment (Abstract #965-P)
• Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes (T2DM) and Moderate Renal Impairment (Abstract #331-OR)
• Rate Ratios for Nocturnal Confirmed Hypoglycaemia with Insulin Degludec vs. Insulin Glargine Using Different Definitions (Abstract #402-P)

The above are a sampling of the abstracts that will be presented or published by Novo Nordisk. A complete listing of abstracts being presented and published at the Scientific Sessions of the ADA can be accessed here.